Latest Biological therapy for inflammatory bowel disease Stories
PRINCETON, N.J., April 14, 2015 /PRNewswire/ -- Soligenix, Inc.
According to an international team of researchers, a parasitic worm found in pigs could modify the human immune system to aid in the treatment of autoimmune diseases.
In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded.
New treatments for inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, diabetes and autism could be on the horizon, after a global University of Melbourne – lead study successfully mapped the genes of a parasitic worm in pigs.
- This Is First Study to Demonstrate Clinical Benefit of Oral alpha 4 Integrin Antagonist in Patient with Inflammatory Bowel Disease - TOKYO, May 13, 2014 /PRNewswire/ -- Ajinomoto
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis.
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder.
BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.